PIZZODIGINO
Pacifico
ALT-005
is being developed by Altacor as a surgical pre-operative antiseptic solution specifically for ophthalmic
use. The potential market for this product is correlated with the large number of ocular surgeries performed
worldwide. For instance, it is estimated that there will be more than 16 million cataract surgeries globally in
2012(3) and more than 1.8 million intravitreal injections were reported in the United States for the 12-month
period ending October 2011(4). A phase 3 study was recently initiated in the United States with ALT-005, with
the second phase 3 study being planned later this year. Altacor plans to file an application for approval of ALT-
005 in selected EU countries and in the United States, where ALT-005 is partnered with a U.S. specialty
company.
Questo ALT 005 deve essere la causa del mancato accordo tra Nicox e Altacor. Vedremo se avrà un futuro o se finirà nel nulla.
use. The potential market for this product is correlated with the large number of ocular surgeries performed
worldwide. For instance, it is estimated that there will be more than 16 million cataract surgeries globally in
2012(3) and more than 1.8 million intravitreal injections were reported in the United States for the 12-month
period ending October 2011(4). A phase 3 study was recently initiated in the United States with ALT-005, with
the second phase 3 study being planned later this year. Altacor plans to file an application for approval of ALT-
005 in selected EU countries and in the United States, where ALT-005 is partnered with a U.S. specialty
company.
Questo ALT 005 deve essere la causa del mancato accordo tra Nicox e Altacor. Vedremo se avrà un futuro o se finirà nel nulla.